ANZICS CTG Endorsed Study

ICU-ROX

A phase 2b, multi-centre, randomised, single blinded clinical trial parallel groups comparing liberal vs. conservative oxygen therapy in mechanically ventilated adults in the Intensive Care Unit (ICU).

Study Description

ICU-ROX is a phase 2b, multi-centre, randomised, single blinded clinical trial parallel groups comparing liberal vs. conservative oxygen therapy in mechanically ventilated adults in the Intensive Care Unit (ICU).

Our study hypothesis is that a conservative approach to oxygen therapy, which minimises unnecessary exposure to hyperoxaemia, will increase ventilator-free days compared to a more liberal approach to oxygen therapy which does not specifically aim to avoid exposure to hyperoxaemia.

Management Committee

Paul Young (Chair), Richard Beasley, Rinaldo Bellomo, Victoria Bennett, Adam Deane, Glenn Eastwood, Simon Finfer, Ross Freebairn, Natalie Linke (Project Manager) Ed Litton, Colin McArthur, Shay McGuinness, Diane Mackle (Project Manager), and Rakshit Panwar.

Administering Institution

Medical Research Institute of New Zealand

Collaborators

ANZIC Research Centre, Monash University

Sample Size

1000 patients

Funding

Health Research Council of New Zealand Project Grant NZ$1,404, 525

Project Status as of June 2019

ICU-ROX finished recruitment in May 2018.  The final 6 month follow-up was conducted in December 2018.  The data have been analysed and manuscript submitted.  The results will be presented at the World Congress of ICU in October 2019.

Contact

Paul Young (email)

Reference

CTG1415-04
ACTRN12615000957594